Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Wed, 20th Nov 2019 13:02

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced the departure of a director and the issue of shares in order to satisfy an GBP82,000 consultancy fee.

The London-headquartered biotechnology firm said Leopoldo Zambeletti has resigned as a non-executive officer.

"The company notes the significant business interests of Mr Zambeletti in a wide range of life sciences companies and expresses its gratitude for Mr Zambeletti's contribution to the company during his tenure," said Tiziana.

Further, the company has issued 190,698 shares at a price of 43 pence each to satisfy a GBP82,000 consultancy fee, without saying to whom it was paying the fee.

Following this, Tiziana will have 136.7 million shares in issue.

Shares in Tiziana were untraded at 41.00p in London on Wednesday during midday trading.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
18 Nov 2020 15:11

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

Read more
11 Nov 2020 20:17

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

Read more
2 Nov 2020 18:14

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

Read more
29 Oct 2020 16:04

Court gives Tiziana capital reduction the nod

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Thursday that the capital reduction required for the demerger of StemPrintER Sciences, and to enable the ultimate allotment of Accustem Sciences shares to its shareholders, has been sanctioned by the court.

Read more
30 Sep 2020 12:18

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

Read more
25 Sep 2020 16:05

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Sep 2020 15:51

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

Read more
16 Sep 2020 11:55

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Read more
24 Aug 2020 14:33

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

Read more
24 Aug 2020 14:19

Tiziana gets US patent for 'TZLS-501' antibody

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.

Read more
21 Aug 2020 09:34

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Read more
18 Aug 2020 18:36

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

Read more
5 Aug 2020 22:03

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

Read more
4 Aug 2020 19:16

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

Read more
4 Aug 2020 11:07

Tiziana inks four deals for development of Covid-19 treatment

(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.